Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
I Ryguła, W Pikiewicz, K Kaminiów - Molecules, 2023 - mdpi.com
Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of
disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of …
disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of …
[HTML][HTML] [Translated article] Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives
M Munera-Campos, JM Carrascosa - Actas dermo-sifiliograficas, 2023 - Elsevier
Abstract The JAK/STAT (Janus kinase/signal transducer and activator of transcription)
pathway is an essential final step in the signaling process of most interleukins with a critical …
pathway is an essential final step in the signaling process of most interleukins with a critical …
Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores
A Wollenberg, D Simon, K Kulthanan… - Journal of the …, 2024 - Wiley Online Library
Background Baricitinib treatment in adults with moderate‐to‐severe atopic dermatitis (AD)
has demonstrated rapid improvements in itch as well as AD sign severity and affected body …
has demonstrated rapid improvements in itch as well as AD sign severity and affected body …
Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension …
K Reich, JI Silverberg, KA Papp… - Journal of the …, 2023 - Wiley Online Library
Background Abrocitinib improved signs and symptoms of moderate‐to‐severe atopic
dermatitis (AD) at Weeks 12 and 16 in phase 3 studies, with a manageable safety profile …
dermatitis (AD) at Weeks 12 and 16 in phase 3 studies, with a manageable safety profile …
[HTML][HTML] Inhibidores de JAK en dermatitis atópica, nuevas perspectivas
M Munera-Campos, JM Carrascosa - Actas Dermo-Sifiliográficas, 2023 - Elsevier
La vía Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) es
esencial en la señalización final de una gran mayoría de interleucinas (IL) fundamentales …
esencial en la señalización final de una gran mayoría de interleucinas (IL) fundamentales …
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis
SG Bridgeman, AK Martino… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction New biologic and small molecule therapeutics have emerged for the treatment
of moderate-to-severe atopic dermatitis (AD), including oral Janus kinase (JAK) inhibitors …
of moderate-to-severe atopic dermatitis (AD), including oral Janus kinase (JAK) inhibitors …
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
G Yosipovitch, P Lio, FJ Legat, R Chovatiya… - Dermatology and …, 2024 - Springer
Background Lebrikizumab demonstrated significant improvement versus placebo for
measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients …
measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients …